PortfoliosLab logo
Fulgent Genetics, Inc. (FLGT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US3596641098

CUSIP

359664109

IPO Date

Sep 29, 2016

Highlights

Market Cap

$619.53M

EPS (TTM)

-$1.33

PEG Ratio

1.32

Total Revenue (TTM)

$292.45M

Gross Profit (TTM)

$111.47M

EBITDA (TTM)

-$47.19M

Year Range

$14.57 - $25.11

Target Price

$22.67

Short %

10.48%

Short Ratio

4.65

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Fulgent Genetics, Inc. (FLGT) returned 10.18% year-to-date (YTD) and -7.96% over the past 12 months.


FLGT

YTD

10.18%

1M

13.94%

6M

17.56%

1Y

-7.96%

5Y*

3.47%

10Y*

N/A

^GSPC (Benchmark)

YTD

1.30%

1M

12.79%

6M

1.49%

1Y

12.35%

5Y*

15.12%

10Y*

10.89%

*Annualized

Monthly Returns

The table below presents the monthly returns of FLGT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-9.91%-7.15%9.39%2.66%17.29%10.18%
2024-14.94%-8.26%-3.81%-6.22%1.47%-4.99%21.97%-5.73%-3.68%-1.29%-14.69%0.93%-36.11%
202313.43%-2.93%-4.79%-5.29%34.49%-6.89%4.86%-15.63%-18.38%-10.47%15.20%4.82%-2.92%
2022-36.50%-2.46%0.18%-12.07%-0.67%0.04%9.57%-27.25%-12.31%3.96%-8.48%-17.89%-70.39%
2021112.07%-8.35%-4.58%-20.29%-3.83%24.52%0.02%-1.09%-1.41%-7.82%12.78%7.56%93.07%
20203.72%10.91%-27.49%57.71%2.65%-8.15%64.69%12.18%35.45%-18.76%38.09%15.98%303.88%
201925.55%13.09%32.19%11.76%-10.68%12.46%-0.30%71.32%-8.94%-7.80%19.00%13.16%306.94%
20182.05%7.16%-16.49%-3.50%-3.70%11.37%15.94%-13.54%-5.30%-9.41%-0.28%-10.70%-27.63%
201712.96%-13.16%-3.79%-6.68%-39.45%3.57%-2.35%-12.98%-11.79%-17.75%-7.36%20.00%-62.14%
20160.44%-2.39%10.78%16.05%26.03%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of FLGT is 40, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of FLGT is 4040
Overall Rank
The Sharpe Ratio Rank of FLGT is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of FLGT is 3737
Sortino Ratio Rank
The Omega Ratio Rank of FLGT is 3636
Omega Ratio Rank
The Calmar Ratio Rank of FLGT is 4444
Calmar Ratio Rank
The Martin Ratio Rank of FLGT is 4242
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Fulgent Genetics, Inc. (FLGT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Fulgent Genetics, Inc. Sharpe ratios as of May 18, 2025 (values are recalculated daily):

  • 1-Year: -0.21
  • 5-Year: 0.06
  • All Time: 0.12

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Fulgent Genetics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Fulgent Genetics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Fulgent Genetics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Fulgent Genetics, Inc. was 91.69%, occurring on Mar 3, 2025. The portfolio has not yet recovered.

The current Fulgent Genetics, Inc. drawdown is 88.93%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.69%Feb 10, 20211019Mar 3, 2025
-77.98%Jan 17, 2017216Nov 21, 2017488Nov 8, 2019704
-65.82%Feb 19, 202019Mar 16, 202083Jul 14, 2020102
-45.97%Aug 21, 202012Sep 8, 202066Dec 10, 202078
-32.49%Nov 11, 20195Nov 15, 201955Feb 6, 202060

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Fulgent Genetics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Fulgent Genetics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 122.3% positive surprise.


0.002.004.006.0020212022202320242025
0.04
-0.18
Actual
Estimate

Valuation

The Valuation section provides an overview of how Fulgent Genetics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for FLGT compared to other companies in the Diagnostics & Research industry. FLGT currently has a PEG ratio of 1.3. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for FLGT relative to other companies in the Diagnostics & Research industry. Currently, FLGT has a P/S ratio of 2.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for FLGT in comparison with other companies in the Diagnostics & Research industry. Currently, FLGT has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items